Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes by Allaman, Igor et al.
ORIGINAL INVESTIGATION
Fluoxetine regulates the expression of neurotrophic/growth
factors and glucose metabolism in astrocytes
Igor Allaman & Hubert Fiumelli & Pierre J. Magistretti &
Jean-Luc Martin
Received: 7 September 2010 /Accepted: 17 January 2011 /Published online: 8 February 2011
# Springer-Verlag 2011
Abstract
Rationale The pharmacological actions of most antidepres-
sants are ascribed to the modulation of serotonergic and/or
noradrenergic transmission in the brain. During therapeutic
treatment for major depression, fluoxetine, one of the most
commonly prescribed selective serotonin reuptake inhibitor
(SSRI) antidepressants, accumulates in the brain, suggest-
ing that fluoxetine may interact with additional targets. In
this context, there is increasing evidence that astrocytes are
involved in the pathophysiology of major depression.
Objectives The aim of this study was to examine the effects
of fluoxetine on the expression of neurotrophic/growth
factors that have antidepressant properties and on glucose
metabolism in cultured cortical astrocytes.
Results Treatment of astrocytes with fluoxetine and parox-
etine, another SSRI antidepressant, upregulated brain-
derived neurotrophic factor (BDNF), vascular endothelial
growth factor (VEGF), and VGF mRNA expression. In
contrast, the tricyclic antidepressants desipramine and
imipramine did not affect the expression of these neuro-
trophic/growth factors. Analysis of the effects of fluoxetine
on glucose metabolism revealed that fluoxetine reduces
glycogen levels and increases glucose utilization and lactate
release by astrocytes. Similar data were obtained with
paroxetine, whereas imipramine and desipramine did not
regulate glucose metabolism in this glial cell population.
Our results also indicate that the effects of fluoxetine and
paroxetine on glucose utilization, lactate release, and
expression of BDNF, VEGF, and VGF are not mediated
by serotonin-dependent mechanisms.
Conclusions These data suggest that, by increasing the
expression of specific astrocyte-derived neurotrophic fac-
tors and lactate release from astrocytes, fluoxetine may
contribute to normalize the trophic and metabolic support to
neurons in major depression.
Keywords Antidepressants . Growth factors . Glia .
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Introduction
Although pharmacological treatment of major depressive
disorder has been available for over 50 years, the cellular
and molecular mechanisms underlying antidepressant treat-
ment remain largely unknown. Most of the antidepressants
available today inhibit the reuptake or breakdown of
serotonin, noradrenaline, or both in the brain. However,
elevation of the extracellular concentration of these mono-
amines, which occurs rapidly, does not explain the time lag
of several weeks to months that is required before a
therapeutic response is achieved (Berton and Nestler
2006; Wong and Licinio 2004).
Selective serotonin reuptake inhibitors (SSRIs) are the
most commonly prescribed drugs for the treatment of
depression. Among SSRIs, fluoxetine is widely used to
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treat depression, and its biochemical and pharmacological
properties have been studied extensively in animals and
humans (Wong et al. 2005). During therapeutic treatment for
major depression, fluoxetine accumulates in the brain, and
fluoxetine concentrations in the 1- to 25-μM range have
been measured by fluorine magnetic resonance spectroscopy
(Bolo et al. 2000; Henry et al. 2005). Because fluoxetine
inhibits serotonin uptake in nerve endings with a Ki value of
0.07 μM (Wong et al. 2005), the brain concentration of
fluoxetine is approximately 15–350 times higher than its
binding affinity for serotonin transporters, suggesting that
fluoxetine may interact with additional targets, including
neurotransmitter- and voltage-gated ion channels (Bianchi
2008; Furutani et al. 2009).
There is increasing evidence indicating that glial cells
are involved in the neuropathology of major depression.
Indeed, post-mortem studies of depressed patients have
revealed a reduced number and an altered morphology of
glial cells in several cortical regions including the prefrontal
and cingulate areas (Cotter et al. 2002; Ongur et al. 1998;
Rajkowska et al. 1999). The decreases in glial cell density
are accompanied by a reduction of astrocytic markers such
as glial fibrillary acidic protein, glial high-affinity glutamate
transporters, and glutamine synthetase in specific areas of
the cerebral cortex from individuals with major depressive
disorder (Choudary et al. 2005; Si et al. 2004), suggesting
that astrocyte dysfunction may contribute to the pathophys-
iology of major depression. Preclinical studies have
recently shown that glial cell loss in the rat prefrontal
cortex is sufficient to induce depressive-like behaviors
(Banasr and Duman 2008). Moreover, administration of
fluoxetine reverses the inhibition of glial cell proliferation
in the medial prefrontal cortex of rats subjected to chronic
psychosocial stress (Czeh et al. 2006).
The possible contribution of astrocytic dysfunction to
major depression and the reversal of stress-induced inhibi-
tion of gliogenesis by fluoxetine led us to hypothesize that
fluoxetine may exert its beneficial effects by acting on
astrocytes.
Although the concept of astrocytes as simple supportive
cells for neurons has been widely accepted for decades,
astrocytes are increasingly recognized to play important
roles in neuronal development, neurotransmission, and
synaptic plasticity (Allen and Barres 2005; Slezak and
Pfrieger 2003; Perea et al. 2009; Halassa and Haydon 2010;
Barker and Ullian 2010). Astrocytes regulate neuronal
survival, neurite outgrowth, and synaptogenesis, and also
provide trophic, structural, and metabolic support to
neurons during development (Wang and Bordey 2008). In
this regard, astrocytes synthesize and release different
trophic factors among which brain-derived neurotrophic
factor (BDNF), fibroblast growth factor 2 (FGF-2), insulin-
like growth factor 1 (IGF-1), and glial cell line-derived
neurotrophic factor (GDNF) have been shown to be
regulated by chronic antidepressant treatment in the
hippocampus (Nibuya et al. 1995; Mallei et al. 2002;
Khawaja et al. 2004; Hisaoka et al. 2007) and to induce
antidepressant-like effects in behavioral models of depres-
sion (Shirayama et al. 2002; Hoshaw et al. 2005; Turner et
al. 2008).
In addition to trophic factors, astrocytes provide essential
energy substrates for neurons to sustain their normal
function and cellular integrity. Although neurons can
import glucose directly from the extracellular space, there
is increasing evidence that glucose is also taken up by
astrocytes, metabolized glycolytically to lactate which is
then released extracellularly to be used by neurons as an
energy substrate to sustain their activity (Rouach et al.
2008; Pellerin et al. 2007).
The aim of this study was to determine whether
astrocytes are a target of fluoxetine by examining the
effects of fluoxetine on the expression of neurotrophic/
growth factors that have antidepressant properties and on
glucose metabolism in cortical astrocytes. We also com-
pared the effects of fluoxetine with those of the SSRI
paroxetine and the tricyclic antidepressants desipramine and
imipramine.
Materials and methods
Reagents
Deoxy-D-glucose, 2-[1,2-3H(N)] (specific activity, 30–
60 Ci/mmol) ([3H]-2-DG) was obtained from ANAWA
(Wangen, Switzerland). Enzymes for glycogen and lactate
release assays as well as NAD, NADP, and ATP were
purchased from Roche Diagnostics (Rotkreuz, Switzer-
land). Fetal calf serum (FCS) was purchased from Bio-
concept (Allschwil, Switzerland). All other chemicals,
including Dulbecco's modified Eagle's mediums (DMEM),
fluoxetine, paroxetine, imipramine, desipramine, and sero-
tonin were obtained from Sigma–Aldrich (Buchs, Switzer-
land). All reagents used to reverse transcribe RNA and to
amplify DNA were purchased from Applied Biosystems
(Rotkreuz, Switzerland).
Cortical astrocyte culture
Primary cultures of cerebral cortical astrocytes were
prepared from 1- to 2-day-old Swiss albino mice (OF1,
Charles River Laboratories, L'Arbresle, France), as previ-
ously described (Allaman et al. 2010). Briefly, brains were
removed aseptically from the skull, meninges were excised
carefully, and the neocortices were dissected. Cells were
dissociated by passages through needles of increasing
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gauges (16-, 19-, and 25-gauge) with a 10-mL syringe
and seeded on polyornithine-coated dishes (35 mm) in
DMEM (D7777) containing 25 mM glucose and supple-
mented with 44 mM NaHCO3, 10 mL/L of a 100×
antibiotic–antimycotic solution (Invitrogen, Basel, Swit-
zerland), and 10% FCS. Cells were incubated at 37°C in
an atmosphere containing 5% CO2–95% air. The culture
medium was renewed 5 days after seeding and, subse-
quently, twice a week. Twenty-one-day-old confluent
cultures were used for all experiments. Using this culture
procedure, >90% of the cells were immunoreactive for
glial fibrillary acidic protein.
Exposure to antidepressants
During all treatments, primary cultures of astrocytes were
maintained at 37°C in an atmosphere containing 5% CO2–
95% air. Twenty-four hours before exposure to antidepres-
sants, the culture medium was removed, and astrocytes
were incubated in serum-free DMEM (D5030) supple-
mented with 5 mM glucose, 44 mM NaHCO3, and 10 mL/L
of an 100× antibiotic–antimycotic solution (Invitrogen)
(DMEM5). Cortical astrocytes were then exposed to the
different antidepressants or serotonin for 24 h.
Quantitative PCR analysis
At the end of the stimulation, cultured cortical astrocytes
were washed twice with 4 mL of ice-cold phosphate-
buffered saline (PBS), and total RNAwas isolated using the
RNeasy Plus Mini Kit (Qiagen, Hombrechtikon, Switzer-
land). The concentration of RNA was determined using a
NanoDrop ND-1000 spectrophotometer (Fisher Scientific,
Wohlen, Switzerland). RNA samples (800 ng) were then
reverse transcribed into first-strand cDNA with the Taq-
Man® reverse transcription reagents and random hexamers,
according to the manufacturer's protocol (Applied Biosys-
tems). Using the Power SYBR Green PCR Master Mix
(Applied Biosystems) and different sets of primers (Table 1)
designed with the Primer Express 3.0 software (Applied
Biosystems), 1/25 of the resulting cDNAwas quantitatively
amplified by real-time PCR with the 7900HT Fast Real-
Time PCR system (Applied Biosystems). The specificity of
PCR amplification for each set of primers was checked by
the presence of a single sharp peak in the melting curve
analysis. Relative mRNA levels were analyzed with qBase
software (Jan Hellemans and Jo Vandesompele, Center for
Medical Genetics, Ghent University Hospital) using a delta-
CT (ΔΔCt) relative quantification model (Livak and
Schmittgen, 2001) with TATA box-binding protein (TBP)
and β-glucuronidase as reference genes. For each mRNA
transcript, data were expressed as fold changes relative to
untreated control cultures.
BDNF ELISA
After treatment with fluoxetine or paroxetine, cultured
cortical astrocytes were washed once with 4 mL of ice-
cold PBS, and cells were harvested in 150 μL lysis buffer
(137 mM NaCl; 20 mM Tris–HCl, pH 8.0; 1% NP-40; 10%
glycerol) containing protease (Complete™, Roche Diagnos-
tic) and phosphatase (Sigma–Aldrich) inhibitor cocktails. A
100-μL aliquot was used to determine BDNF cellular
content using the BDNF Emax
® Immunoassay System
(Promega, Dübendorf, Switzerland), according to the
manufacturer's instructions. Absolute values were deter-
mined from a standard curve. The protein content was
measured in the remaining cell lysate with the BCA protein
assay reagent kit (Pierce, Lausanne, Switzerland), and
values were expressed as picograms of BDNF per milli-
gram of protein.
[3H]-2-DG uptake
[3H]-2-DG uptake experiments were conducted as previ-
ously described (Allaman et al. 2010). After treatment with
antidepressants or serotonin, [3H]-2-DG assay was initiated
by replacing the medium with 2 mL of DMEM5 containing
1 μCi/mL [3H]-2-DG. The cells were incubated for an
additional 20 min at 37°C in an atmosphere containing 5%
Table 1 Primer sequences for quantitative PCR analysis
Gene Sense primer Antisense primer Accession number
β-glucuronidase GGGCATTTGGAGGTGATTCA TGCTCCATACTCGCTCTGGAT NM_010368
BDNF AAAACCATAAGGACGCGGACTT GAGGCTCCAAAGGCACTTGA NM_007540
FGF-2 GCGACCCACACGTCAAACTA GGTACCGGTTGGCACACAT NM_008006
GDNF TGACTCCAATATGCCTGAAGATTATC TCAGTCTTTTAATGGTGGCTTGAA NM_010275
IGF-1 CCCGTCCCTATCGACAAACA TTCCTGCACTTCCTCTACTTGTGT NM_010512
TBP CAACAGCCTTCCACCTTATGC CATTGGACTAAAGATGGGAATTCC NM_013684
VEGF GCAGGCTGCTGTAACGATGA TTGATCCGCATGATCTGCAT NM_001025250
VGF CAGCCCGTTGGTCATGAAA CTCCCAACCCCTGGATCAGT NM_001039385
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CO2–95% air. The uptake was terminated by collecting the
culture medium (for lactate release assay, see below) and by
washing the cells three times with 4 mL of ice-cold PBS.
Cells were then lysed by the addition of 2 mL of 10 mM
NaOH containing 0.1% Triton X-100. Five hundred-
microliter aliquots, in duplicate, were assayed for radioac-
tivity by liquid scintillation counting. Results, which
represent the transporter-mediated glucose uptake and
subsequent phosphorylation, were calculated by subtracting
from total counts the portion that was not inhibited by the
glucose transporter inhibitor cytochalasin B (25 μM) added
20min prior to and along [3H]-2-DG incubation. The medium
used for [3H]-2-DG uptake was pre-equilibrated at 37°C in
an atmosphere containing 5% CO2–95% air. The protein
content was measured in the remaining lysate with the BCA
protein assay reagent kit (Pierce) according to the manufac-
turer's instructions. [3H]-2-DG uptake was expressed as
fentomoles per milligram of protein.
Lactate release
Lactate released by astrocytes was determined as previously
described (Allaman et al. 2010). Briefly, 100-μL aliquots of
the culture medium used for [3H]-2-DG incubation were
mixed with 1 mL of glycine buffer (0.2 mM, pH 10)
containing 2 mg/mL NAD and 7 U/mL lactate dehydroge-
nase and incubated at 40°C for 1 h. After 20 min at room
temperature, the amount of NADH produced was measured
by fluorescence at 340/450 nm (excitation/emission) in a
200-μL aliquot loaded on a 96-well plate using a
spectrophotometer (Safire 2, TECAN, Männedorf, Switzer-
land), and absolute values of lactate were determined from
a standard curve. Lactate release into the medium was
expressed as nanomoles per milligram of protein.
Glycogen assay
At the end of the treatments, astrocytes were rinsed three
times with ice-cold PBS and lysed by sonication in 1.5 mL
of 30 mM HCl. Glycogen content of the cell extract was
determined enzymatically as previously described (Allaman
et al. 2004). Briefly, two 100-μL aliquots were sampled in
duplicate. Acetate buffer, 300 μL (0.1 M, pH 4.65), was
added to the first aliquot, and 300 μL of the same acetate
buffer containing 1% (v/v) amyloglucosidase (140 U/mL)
was added to the other. After incubation (30 min at room
temperature), 2 mL of Tris–HCl buffer (0.1 mM, pH 8.1)
containing 3.3 mM MgCl2, 0.2 mM ATP, 25 μg/mL NADP,
0.7 U/mL hexokinase, and 0.35 U/mL glucose-6-phosphate
dehydrogenase were added to the aliquots, and the mixture
was incubated for 30 min at room temperature. The
fluorescence of the NADPH formed was determined at
340/450 nm (excitation/emission) using a fluorometer and a
glucose standard curve. The first aliquot provided the signal
generated by glucose and glucose-6-phosphate, while the
second aliquot corresponded to the signal generated by
glycogen plus glucose and glucose-6-phosphate. The
amount of glycogen was determined by the difference
between the two signals. It is important to note that,
hereafter, “1 mole of glycogen” represents 1 mole of
glycosyl unit originating from glycogen. The protein content
of the cell lysate was determined using the BCA protein
assay reagent kit (Pierce), and the glycogen cell content was
expressed as nanomoles per milligram of protein.
Statistical analysis
Data were analyzed for statistical significance with Stu-
dent's t test or by one-way ANOVA, followed either by
Dunnett's or Bonferroni's post hoc test, using InStat 3.0
software (GraphPad, San Diego, CA).
Results
Among neurotrophic/growth factors that are synthesized by
astrocytes, BDNF, FGF-2, IGF-1, and GDNF are regulated
by antidepressant treatments (Nibuya et al. 1995; Mallei et
al. 2002; Khawaja et al. 2004; Hisaoka et al. 2007) and
produce antidepressant-like effects in behavioral models of
depression (Shirayama et al. 2002; Hoshaw et al. 2005;
Turner et al. 2008), suggesting that these neurotrophic/
growth factors may contribute to the therapeutic action of
antidepressant treatment. On the basis of these observa-
tions, we examined whether fluoxetine, one of the most
commonly prescribed antidepressants, regulates the expres-
sion of BDNF, FGF-2, IGF-1, and GDNF in cortical
astrocytes. Quantitative PCR analysis revealed that treat-
ment of cortical astrocytes with 10 μM fluoxetine increased
BDNF mRNA levels (212.1±10.3% of the control), while
IGF-1 and GDNF mRNA levels remained unchanged
(Fig. 1). Levels of FGF-2 mRNA showed a tendency to
increase with fluoxetine which was not, however, statisti-
cally significant (Fig. 1). In addition to BDNF, FGF-2, IGF-
1, and GDNF, we investigated whether fluoxetine affects
the expression of vascular endothelial growth factor
(VEGF) and VGF, two growth factors that produce
antidepressant-like effects in behavioral models of depres-
sion (Warner-Schmidt and Duman 2007, 2008; Thakker-
Varia et al. 2007; Hunsberger et al. 2007). Exposure of
cortical astrocytes to fluoxetine caused a marked enhance-
ment of VEGF and VGF mRNA levels (377.8±32.0% and
226.3±17.4% of controls, respectively; Fig. 1). Consistent
with these data, paroxetine, another SSRI antidepressant,
upregulated BDNF, VEGF, and VGF mRNA levels,
without significantly affecting the expression levels of
78 Psychopharmacology (2011) 216:75–84
FGF-2, GDNF, and IGF-1 mRNAs (Fig. 2). The increase in
BDNF mRNA levels by fluoxetine and paroxetine were
confirmed at the protein level by ELISA. Thus, fluoxetine
and paroxetine enhanced BDNF protein levels in cortical
astrocytes by 2.5- and 5.7-fold, respectively (control, 2.9±
0.2 pg/mg protein; fluoxetine, 7.2±0.2 pg/mg protein; and
paroxetine, 16.5±2.3 pg/mg protein; mean±SEM of nine
determinations from three independent experiments;
P<0.05 between control and fluoxetine-treated groups and
P<0.01 between control and paroxetine-treated groups by
ANOVA followed by Dunnett's test). In contrast to the
effects of the SSRIs fluoxetine and paroxetine, the tricyclic
antidepressants desipramine and imipramine did not affect
the expression of these neurotrophic/growth factors in
cortical astrocytes (Fig. 2).
In addition to supplying neurotrophic/growth factors,
there is ample evidence that astrocytes provide essential
energy substrates to neurons (Magistretti 2008). In partic-
ular, it has been shown that glucose is taken up by
astrocytes and metabolized glycolytically to lactate which
is then released in the extracellular space and oxidized by
neurons to meet part of their energy needs (Pellerin et al.
2007). These observations led us to examine whether
fluoxetine alters the release of lactate from cortical
astrocytes. Treatment of cortical astrocytes with fluoxetine
resulted in an increased lactate release (125.0±7.6% of the
control; Fig. 3a). Similar data were obtained with parox-
etine, while imipramine and desipramine did not affect
lactate release from astrocytes (Fig. 3a). We next examined
whether the increased release of lactate by fluoxetine was
coupled with an enhancement of glucose utilization by
astrocytes. Treatment of cortical astrocytes with fluoxetine
resulted in an increased glucose utilization (126.0±6.8% of
the control), as shown by the stimulation of [3H]-2-DG
uptake by astrocytes (Fig. 3b). Consistent with the data
from the lactate release experiments (Fig. 3a), paroxetine
enhanced [3H]-2-DG uptake, whereas the tricyclic antide-
pressants imipramine and desipramine had no significant
effect on glucose utilization by astrocytes (Fig. 3b).
Glycogen is the major energy reserve of the brain and is
localized almost exclusively in astrocytes (Magistretti et al.
1993; Brown and Ransom 2007). Compelling evidence
indicates that mobilization of astrocyte glycogen can
provide additional energy substrates for neurons when
energy demand exceeds glucose supply (Brown and
Ransom 2007). We therefore examined whether fluoxetine
regulates glycogen levels in astrocytes. Our studies
revealed that treatment of cortical astrocytes with fluoxetine
and paroxetine decreased glycogen levels (77.7±2.2% and
63.1±4.4% of the control, respectively), whereas neither
imipramine nor desipramine altered glycogen metabolism
(Fig. 3c). Reduction of glycogen levels by fluoxetine in
astrocytes is consistent with previous observations (Zhang
et al. 1993). Together, these results indicate that fluoxetine
and paroxetine regulate glycogen levels, glucose utilization,
and lactate release by cortical astrocytes (Fig. 3).
As SSRIs increase the extracellular level of serotonin
within the synaptic cleft by inhibiting its reuptake into the
presynaptic cell, we next examined whether the effects of
fluoxetine on the expression of neurotrophic/growth factors
and glucose metabolism in cortical astrocytes were medi-
ated by serotonin. We addressed this issue by investigating
whether regulation of glycogen levels, glucose utilization,
lactate release, and expression of neurotrophic/growth
factors by serotonin was similar to that by fluoxetine.
Consistent with previous observations (Magistretti et al.
Fig. 2 Paroxetine, but not imipramine and desipramine, upregulates
BDNF, VEGF, and VGF mRNA levels in cortical astrocytes.
Astrocytes were treated with (10 μM) paroxetine, imipramine, or
desipramine for 24 h, and mRNA levels of BDNF, FGF-2, GDNF,
IGF-1, VEGF, and VGF were analyzed by quantitative PCR. Results
are expressed as percentages of the control (Ctrl) value for each
neurotrophic/growth factor and are the means±SEM of at least 14
determinations from 5 independent experiments. Data were statisti-
cally analyzed by ANOVA followed by Bonferroni's test. *P<0.05
versus Ctrl, ***P<0.001 versus Ctrl
Fig. 1 Fluoxetine increases the expression of BDNF, VEGF, and
VGF mRNAs in cortical astrocytes. Astrocytes were exposed to
10 μM fluoxetine for 24 h, and mRNA levels of BDNF, FGF-2,
GDNF, IGF-1, VEGF, and VGF were analyzed by quantitative PCR.
Results are expressed as percentages of control (Ctrl) values for each
neurotrophic/growth factor and are the means±SEM of at least 37
determinations from 12 independent experiments. Data were statisti-
cally analyzed using ANOVA followed by Bonferroni's test.
***P<0.001 versus Ctrl
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1983), stimulation of cortical astrocytes by serotonin
resulted in reduced glycogen levels (75.3±2.2% of the
control, Fig. 4a). In contrast, serotonin did not affect [3H]-
2-DG uptake, lactate release, and levels of BDNF, FGF-2,
GDNF, IGF-1, VEGF, and VGF mRNAs (Fig. 4b–d). These
data indicate that the effects of fluoxetine and paroxetine on
glucose utilization, lactate release, and the expression of
BDNF, VEGF, and VGF mRNAs in cortical astrocytes are
not mediated by serotonin-dependent mechanisms.
Fig. 3 Fluoxetine and paroxetine, but not imipramine and desipramine,
regulate lactate release, glucose utilization, and glycogen levels in cortical
astrocytes. Astrocytes were exposed to (10 μM) fluoxetine (Fluo),
paroxetine (Paro), imipramine (Imi), or desipramine (Desi) for 24 h, and
lactate release, glucose utilization, and glycogen levels were measured. a
Lactate release. Results are expressed as percentages of the control (Ctrl)
value (1,922.0±95.4 nmol/mg prot) and are the means±SEM of at least
11 determinations from 4 independent experiments. b Glucose utilization
as determined using the [3H]-2-DG uptake technique. Results are
expressed as percentages of the Ctrl value (336.2±14.3 fmol of [3H]-2-
DG uptake/mg prot) and are the means±SEM of at least 11 determi-
nations from 4 independent experiments. c Glycogen levels. Results are
expressed as percentages of the Ctrl value (60.9±4.1 nmol/mg prot) and
are the means±SEM of at least 9 determinations from 3 independent
experiments. All data were statistically analyzed with ANOVA followed
by Dunett's test. *P<0.05 versus Ctrl, **P<0.01 versus Ctrl
Fig. 4 Effects of serotonin on glucose metabolism and neurotrophic/
growth factor expression in cortical astrocytes. Astrocytes were
exposed to 100 μM serotonin for 24 h, and glycogen levels, glucose
utilization, lactate release, and expression of neurotrophic/growth
factors were measured. a Glycogen levels. Results are expressed as
percentages of the control (Ctrl) value (45.0±1.7 nmol/mg prot) and
are the means±SEM of at least 8 determinations from 3 independent
experiments. b Glucose utilization as determined using the [3H]-2-DG
uptake technique. Results are expressed as percentages of the Ctrl
value (253.3±15.4 fmol of [3H]-2-DG uptake/mg prot) and are the
means±SEM of 15 determinations from 5 independent experiments. c
Lactate release. Results are expressed as percentages of the Ctrl value
(1,445.7±125.17 nmol/mg prot) and are the means±SEM of 15
determinations from 5 independent experiments. d Analysis of BDNF,
FGF-2, GDNF, IGF-1, VEGF, and VGF mRNA levels by quantitative
PCR. Results are expressed as percentages of the Ctrl value for each
neurotrophic/growth factor and are the means±SEM of 9 determi-
nations from 3 independent experiments. Data shown in a, b and c
were statistically analyzed by ANOVA followed by t test
(***P<0.0001). Data shown in d were statistically analyzed using
ANOVA followed by Bonferroni's test (no significant differences
between Ctrl and serotonin conditions)
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Discussion
Data from the current study indicate that fluoxetine and
paroxetine increase the expression of BDNF, VEGF, and
VGF; glucose utilization; and lactate release from cortical
astrocytes by serotonin-independent mechanisms. In con-
trast, the tricyclic antidepressants desipramine and imipra-
mine neither affect the expression of these neurotrophic/
growth factors nor glucose metabolism in this glial cell
population.
In vivo imaging studies of patients with major depres-
sion have shown that the hippocampus and prefrontal
cortex undergo selective volume reductions (Drevets
2000a; Bremner et al. 2002; Sheline 2003). Moreover,
post-mortem histological analysis of the prefrontal cortex of
patients suffering from major depressive disorder has
demonstrated reductions in the number and density of glial
cells and in the size of neuronal cell bodies, which may
contribute to these volume reductions (Rajkowska and
Miguel-Hidalgo 2007; Cotter et al. 2002; Ongur et al.
1998). Interestingly, decreases in glial cell density in the
prefrontal cortex of depressed patients are accompanied by
a reduction of astrocytic markers (Choudary et al. 2005; Si
et al. 2004), suggesting that an astrocytic deficit may
contribute to the etiology of major depression. In support of
this hypothesis, glial ablation in the prefrontal cortex is
sufficient to induce depressive-like behaviors (Banasr and
Duman 2008).
Astrocytes have important functions that include the
promotion of neuronal maturation, synapse formation, and
neuronal survival during development, the regulation of
angiogenesis, and the maintenance of a viable microenvi-
ronment for neurons (Wang and Bordey 2008). In this
context, astrocytes provide neurotrophic/growth factors and
energy substrates that are essential for neuronal survival
and neurite outgrowth (Wang and Bordey 2008). Among
neurotrophic/growth factors that we found to be expressed
in cortical astrocytes, BDNF, VEGF, and VGF are
upregulated by fluoxetine (Fig. 1).
BDNF regulates the survival and differentiation of
specific subsets of neurons in the central and peripheral
nervous systems (Jones et al. 1994; Lewin and Barde
1996). In the central nervous system, BDNF controls
dendritic growth (McAllister et al. 1995, 1996) and
provides trophic support to a variety of neurons including
cortical and hippocampal neurons (Ghosh et al. 1994;
Lindholm et al. 1996). These observations suggest that
selective reductions in the volume of the prefrontal cortex
and hippocampus of depressed patients may result from the
reduced supply of BDNF. In support of this hypothesis,
post-mortem analysis of brain tissue has revealed that the
expression of BDNF is decreased in the hippocampus of
depressed suicide victims compared to that of healthy
controls (Chen et al. 2001; Dwivedi et al. 2003). Therefore,
the increased expression of BDNF by fluoxetine in cortical
astrocytes (Fig. 1) may contribute to block or reverse
neuronal atrophy and cell loss observed in the prefrontal
cortex of depressed patients.
VEGF was originally described as an endothelial cell
mitogen and survival factor that regulates angiogenesis and
vascular permeability (Ferrara et al. 2003). More recent
studies have provided evidence that VEGF increases the
proliferation of neuronal progenitors (Wada et al. 2006),
stimulates adult neurogenesis (Jin et al. 2002), and
promotes neurite outgrowth (Jin et al. 2006; Rosenstein et
al. 2003; Khaibullina et al. 2004). In addition, VEGF has
been shown to contribute to the actions of antidepressant
treatment. Thus, chronic antidepressant administration
increases VEGF expression in the hippocampus (Warner-
Schmidt and Duman 2007), and infusion of VEGF into the
lateral ventricles enhances neurogenesis and produces
antidepressant responses in different animal models of
depression (Warner-Schmidt and Duman 2007). Recent
observations indicate that VEGF is required for the effects
of fluoxetine in different behavioral paradigms and that
chronic administration of fluoxetine increases VEGF
expression in neurons and endothelial cells of the hippo-
campus (Greene et al. 2009). Interestingly, our data extend
these observations by demonstrating that, in addition to
neurons and endothelial cells, fluoxetine can also regulate
VEGF expression in astrocytes (Fig. 1). In this context, it is
of interest that the mood stabilizer lithium upregulates the
expression of VEGF in cortical astrocytes (Guo et al. 2009).
Because VEGF increases cell body diameter and neurite
outgrowth from cortical neurons (Rosenstein et al. 2003) as
well as astroglial proliferation (Krum et al. 2002), this
suggests that upregulation of VEGF expression by fluox-
etine in cortical astrocytes (Fig. 1) may contribute to
reverse the structural changes in the prefrontal cortex of
depressed patients.
VGF is a secreted neuropeptide that is involved in the
regulation of energy balance and synaptic plasticity (Alder
et al. 2003; Salton et al. 2000). More recently, VGF has
been shown to induce antidepressant-like actions in rodents
(Hunsberger et al. 2007; Thakker-Varia et al. 2007). Thus,
local infusion of VGF into the midbrain or hippocampus
produces antidepressant responses in several animal models
of depression (Thakker-Varia et al. 2007; Hunsberger et al.
2007), and heterozygous VGF+/− mice exhibit an increased
depression-like behavior (Hunsberger et al. 2007). There is
also evidence that VGF is upregulated in the rodent
hippocampus after manipulations that have antidepressant-
like activity (Hunsberger et al. 2007; Thakker-Varia et al.
2007; Newton et al. 2003). Our data showing that
fluoxetine upregulates VGF expression in cortical astro-
cytes (Fig. 1) are in line with recent findings, demonstrating
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that chronic treatment with fluoxetine increases VGF
mRNA levels in the rat hippocampus and prefrontal cortex
(Cattaneo et al. 2010). However, to our knowledge, this is
the first observation of an upregulation of VGF expression
by an antidepressant in non-neuronal cells. Upregulation of
VGF expression by fluoxetine in cortical astrocytes may be
mediated by BDNF, as we found that fluoxetine increases
BDNF expression (Fig. 1), and it has been shown that
BDNF induces VGF expression (Bonni et al. 1995).
The roles of VGF in depression and antidepressant
actions (Thakker-Varia and Alder 2009; Malberg and
Monteggia 2008) suggest that the upregulation of VGF
expression by fluoxetine in astrocytes may contribute to its
antidepressant actions.
Astrocytes play an essential role in brain energy
metabolism by providing energy substrates for neurons
(Magistretti 2008). Although glucose is the obligatory
energy substrate for the brain under normal resting
conditions, there is increasing evidence that lactate released
by astrocytes can be used by neurons to sustain their
synaptic activity (Rouach et al. 2008; Pellerin et al. 2007).
Lactate is an energy substrate that preserves neuronal
function in experimental models of excitotoxicity (Maus
et al. 1999), posthypoxic recovery (Schurr et al. 1997a, b),
cerebral ischemia (Schurr et al. 1997b), and energy
deprivation (Cater et al. 2001), highlighting the importance
of astrocyte-derived lactate for neuronal function and
viability.
In unmedicated subjects with familial major depressive
disorder, glucose metabolism is reduced in the dorsome-
dial/dorsal anterolateral prefrontal cortex and subgenual
prefrontal cortex (Drevets 2000b, 2001), while treatment
with fluoxetine normalizes the frontal hypometabolism
(Mayberg et al. 2000). These observations suggest that the
increased release of lactate by cortical astrocytes in
response to fluoxetine (Fig. 3a) may contribute to protect
neurons from the damaging effects of stress, a critical
factor in the etiology of depression, and to normalize the
hypometabolism in the prefrontal cortex of depressed
patients.
Among other energy substrates that support energy-
dependent processes in the brain, glycogen, which is found
primarily in astrocytes (Magistretti et al. 1993), provides an
important energy source during periods of increased energy
demand when glucose supply is not sufficient to meet the
transient elevation in energy requirements (Brown and
Ransom 2007). Glycogenolysis is particularly well suited to
rapidly provide large amounts of glycolytically derived
energy because, in contrast to glycolysis, it does not require
ATP expenditure to phosphorylate glucose, and breakdown
of glycogen to pyruvate produces more energy than the
formation of pyruvate from glucose. Astrocyte glycogen
can be metabolized to lactate which is exported to the
extracellular space and taken up by neurons to be used as
an aerobic substrate (Brown and Ransom 2007). These
observations suggest that the increased release of lactate by
fluoxetine in cortical astrocytes (Fig. 3a) may result not
only from the stimulation of glucose utilization (Fig. 3b),
but also from the degradation of glycogen (Fig. 3c).
Glycogen degradation to lactate and transfer of lactate from
astrocytes to neurons may be required to support the
increased energy demand associated with the neurotrophic
effects induced by fluoxetine through BDNF, VEGF, and
VGF.
Recent data show that glycogen plays an important role
in sustaining glutamatergic neurotransmission (Sickmann et
al. 2009). In particular, energy derived from glycogen
breakdown was demonstrated to be necessary for the
maintenance of sodium-dependent glutamate transport
capacity in astrocytes (Sickmann et al. 2009). Interestingly,
accumulating evidence suggests the existence of abnormal-
ities in the glutamatergic system of patients with major
depressive disorder. For example, elevated levels of
glutamate were measured in the occipital cortex of
individuals diagnosed with major depressive disorder
(Sanacora et al. 2004) and in post-mortem frontal cortex
from patients with major depression (Hashimoto et al.
2007). These observations suggest that stimulation of
glycogenolysis by fluoxetine may contribute to provide
enough energy for the enhanced astrocyte glutamate uptake
associated with elevated glutamate levels in patients with
major depression.
Brain imaging and post-mortem studies have revealed
structural alterations in patients with major depressive
disorder that result from reductions in neuronal size and
decreases in the numbers of neurons and glia in these brain
regions (Rajkowska 2000; Rajkowska and Miguel-Hidalgo
2007). Reductions in neuronal size and density may be due,
in part, to a decreased ability of astrocytes to provide
trophic and metabolic support to neurons. Results of this
study suggest that, by increasing the expression of specific
astrocyte-derived neurotrophic/growth factors and lactate
release from astrocytes, fluoxetine may contribute to
normalize the trophic and metabolic support to neurons in
major depression. In contrast, the tricyclic antidepressants
desipramine and imipramine do not regulate the expression
of neurotrophic/growth factors and glucose metabolism in
astrocytes, suggesting that the therapeutic effects of
desipramine and imipramine are not mediated by this glial
cell population or involve other astrocytic mechanisms that
remain to be elucidated.
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